Crown Bioscience Joins C-Path NAMs Coalition to Validate Human-Relevant Preclinical Models
- Crown Bioscience, an oncology-focused CRO, joined Critical Path Institute's New Approach Methodologies Developer Coalition to advance regulatory acceptance of human-relevant preclinical models.
- The company will contribute expertise in patient-derived xenografts, organoids, ex vivo tissue platforms, and biomarker analysis while expanding capabilities in organoid toxicology and organ-on-chip collaborations.
- Coalition membership positions Crown Bioscience as an active contributor to regulatory qualification frameworks aligned with FDA Modernization Act 2.0 and emerging EMA guidance.
Operational Impact
Crown Bioscience's NAMs-DC membership strengthens its competitive positioning for oncology sponsors seeking preclinical partners whose human-relevant model platforms are validated within regulatory qualification frameworks, reducing sponsor risk in regulatory submissions.
Source: PharmaSource RSS